Clinical Trial Results:
Use of genotypic HIV-1 tropism testing in proviral DNA to guide CCR5 antagonist treatment in subjects with undetectable HIV-1 viremia
Summary
|
|
EudraCT number |
2011-000799-32 |
Trial protocol |
ES |
Global end of trial date |
29 May 2014
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
30 Dec 2016
|
First version publication date |
30 Dec 2016
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
PROTEST
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT01378910 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Fundació Lluita contra la SIDA
|
||
Sponsor organisation address |
crta. canyet, s/n, Badalona, Spain, 08916
|
||
Public contact |
Unitat VIH, Fundació Lluita contra la SIDA, +34 934978849, rescrig@fls-rs.com
|
||
Scientific contact |
Unitat VIH, Fundació Lluita contra la SIDA, +34 934978849, rescrig@fls-rs.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
29 May 2014
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
29 May 2014
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
Assess whether the determination of viral tropism from proviral DNA in PBMCs is a suitable technique to guide treatment with CCR5 antagonists in patients with undetectable viral load who need antiretroviral treatment change for reasons of tolerability or adverse effects.
|
||
Protection of trial subjects |
not specific
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
01 Jun 2011
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Spain: 74
|
||
Worldwide total number of subjects |
74
|
||
EEA total number of subjects |
74
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
74
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||
Recruitment details |
Subjects who met inclusion criteria and accepted to sign the informed consent to participate will be cited for a screening visit and blood sample collection for HIV tropism determination. A total of 175 HIV-infected patients were selected at the screening phase | ||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||
Screening details |
A total of 175 HIV-infected patients were selected at the screening phase. | ||||||||||||||||||||
Period 1
|
|||||||||||||||||||||
Period 1 title |
overall trial (overall period)
|
||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||
Allocation method |
Not applicable
|
||||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||||
Arms
|
|||||||||||||||||||||
Arm title
|
maraviroc in combination with 2 NRTIs | ||||||||||||||||||||
Arm description |
- | ||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||
Investigational medicinal product name |
maraviroc
|
||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||
Other name |
|||||||||||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||
Dosage and administration details |
not available
|
||||||||||||||||||||
Investigational medicinal product name |
lamivudine
|
||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||
Other name |
|||||||||||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||
Dosage and administration details |
not available
|
||||||||||||||||||||
Investigational medicinal product name |
abacavir
|
||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||
Other name |
|||||||||||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||
Dosage and administration details |
not available
|
||||||||||||||||||||
Investigational medicinal product name |
emtricitabine
|
||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||
Other name |
|||||||||||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||
Dosage and administration details |
not available
|
||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
overall trial
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
maraviroc in combination with 2 NRTIs
|
||
Reporting group description |
- |
|
|||||||
End point title |
virological efficacy [1] | ||||||
End point description |
|||||||
End point type |
Primary
|
||||||
End point timeframe |
week 48
|
||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: For the primary endpoint we calculate the sample size. We suppose a 95% confidence interval, a 6% precision and we assume that 85% of patients would remain suppressed after 48 weeks. At the end of the study 84% (N=62 out of 74) of HIV-infected patients switching to maraviroc plus 2 NRTIs maintained HIV-RNA levels below 50 cop/mL . This estimate had a final precision of 8.3%, which is slightly lower than the one initially planned (i.e.: 6%) |
|||||||
|
|||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Total cholesterol | ||||||||
End point description |
|||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Baseline
|
||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
week 48
|
||||||||||||||||||||||||||||||
Assessment type |
Non-systematic | ||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||
Dictionary name |
DAIDS AE GRADING TAB | ||||||||||||||||||||||||||||||
Dictionary version |
2.0
|
||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||
Reporting group title |
maraviroc in combination with 2 NRTIs
|
||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 0% | |||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
02 Jun 2011 |
new sites added in clinical trial |
||
27 Jul 2011 |
Principal investigator changed |
||
29 Jun 2012 |
new sites added in clinical trial |
||
03 Oct 2012 |
New Principal investigator added in one site already opened |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |